1α, 25-dihydroxyvitamin D 3 reduces c-Myc expression, inhibiting proliferation and causing G 1 accumulation in C4-2 prostate cancer cells

Endocrinology

Volumn 150, Issue 5, 2009, Pages 2046-2054

  Rohan, Joyann N Phillips ^a   Weigel, Nancy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; GLYCOGEN SYNTHASE KINASE 3BETA; MYC PROTEIN; WNT PROTEIN; MYC PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; CELL CULTURE; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; ONCOGENE MYC; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CALCITRIOL; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 66449120903     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-1395     Document Type: Article

References (76)

1. Masuda S, Jones G 2006 Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol Cancer Ther 5:797-808
2. Barreto AM, Schwartz GG, Woodruff R, Cramer SD 2000 25-Hydroxyvita- min D3, the prohormone of 1, 25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 9:265-270
3. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P 2000 Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11:847-852
4. John EM, Koo J, Schwartz GG 2007 Sun exposure and prostate cancer risk: evidence for a protective effect of early-life exposure. Cancer Epidemiol Biomarkers Prev 16:1283-1286
5. John EM, Schwartz GG, Koo J, Van Den Berg D, Ingles SA2005 Sunexposure, vitamin Dreceptor genepolymorphisms, and riskofadvancedprostatecancer. Cancer Res 65:5470-5479
6. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB 2008 Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100:796-804
7. Haussler MR, Mangelsdorf DJ, Komm BS, Terpening CM, Yamaoka K, Allegretto EA, Baker AR, Shine J, McDonnellDP, Hughes M, WeigelNL, O'Malley BW, Pike JW 1988 Molecular biology of the vitamin D hormone. Recent Prog Horm Res 44:263-305
8. Moffatt KA, Johannes WU, Hedlund TE, Miller GJ 2001 Growth inhibitory effects of 1a, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res 61:7122-7129
9. Skowronski RJ, Peehl DM, Feldman D 1993 Vitamin D and prostate cancer: 1, 25 dihydroxyvitaminD3 receptorsandactionsinhumanprostatecancercell lines. Endocrinology 132:1952-1960
10. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL 2000 A calcitriol analogue, EB1089, inhibitsthegrowthofLNCaPtumorsinnudemice. Cancer Res 60:779-782
11. Trump DL, Hershberger PA, Bernard! RJ, Ahmed S, Muindi J, Fakih M, Yu WD, Johnson CS 2004 Anti-tumor activity of calcitriol: pre-clinical and clinical studies. JSteroid Biochem Mol Biol 89-90:519-526
12. Blutt SE, Allegretto EA, Pike JW, Weigel NL19971, 25-DihydroxyvitaminD3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 138: 1491-1497
13. Blutt SE, McDonnell TJ, Polek TC, Weigel NL 2000 Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141:10 -17
14. Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler HP 1995 20-Epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 55:2822-2830
15. Simboli-Campbell M, Narvaez CJ, van Weelden K, Tenniswood M, Welsh J 1997 Comparative effects of 1, 25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 42:31-41
16. Studzinski GP, Bhandal AK, Brelvi ZS 1985 Cell cycle sensitivity of HL-60 cells to the differentiation-inducing effects of 1-a, 25-dihydroxyvitamin D3. Cancer Res 45:3898-3905
17. Yang ES, Burnstein KL2003 VitaminDinhibitsG1toSprogressioninLNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. JBiol Chem 278:46862-46868
18. Boyle BJ, Zhao XY, Cohen P, Feldman D 2001 Insulin-like growth factor binding protein-3 mediates 1a, 25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165:1319 -1324
19. Polek TC, StewartLV, Ryu EJ, Cohen MB, AllegrettoEA, WeigelNL2003 p53 isrequiredfor1, 25-dihydroxyvitaminD3-inducedG0arrestbutisnotrequired for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 144:50-60
20. Mateyak MK, Obaya AJ, Sedivy JM1999 c-MycregulatescyclinD-Cdk4and -Cdk6 activitybutaffectscellcycleprogressionatmultipleindependentpoints. Mol Cell Biol 19:4672-4683
21. Popescu NC, Zimonjic DB 2002 Chromosome-mediated alterations of the MYC gene in human cancer. J Cell Mol Med 6:151-159
22. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR 2007 Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 67:8504-8510
23. Jenkins RB, Qian J, Lieber MM, Bostwick DG 1997 Detection of c-myc on- cogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57:524-531
24. Thompson TC, Southgate J, Kitchener G, Land H 1989 Multistage carcino- genesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56: 917-930
25. Williams K, Fernandez S, Stien X, Ishii K, Love HD, Lau YF, Roberts RL, Hayward SW 2005 Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate 63:369-384
26. Thompson TC, Egawa S, Kadmon D, Miller GJ, Timme TL, ScardinoPT, Park SH 1992 Androgen sensitivity and gene expression in ras + myc-induced mouse prostate carcinomas. JSteroid Biochem Mol Biol 43:79-85
27. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL 2003 Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4:223-238
28. Dwyer J, Li H, Xu D, Liu JP 2007 Transcriptional regulation of telomerase activity: roles of the Ets transcription factor family. Ann NY Acad Sci 1114: 36-47
29. Dean M, Levine RA, Ran W, Kindy MS, Sonenshein GE, Campisi J 1986 Regulation of c-myc transcription and mRNA abundance by serum growth factors and cell contact. J Biol Chem 261:9161-9166
30. Sun J, Jin T 2008 Both Wnt and mTOR signaling pathways are involved in insulin-stimulated proto-oncogene expression in intestinal cells. Cell Signal 20:219-229
31. He TC, Sparks AB, Rago C, HermekingH, ZawelL, daCostaLT, MorinPJ, VogelsteinB, KinzlerKW 1998 Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512
32. Pan Q, Simpson RU 1999 c-myc intron element-binding proteins are required for 1, 25-dihydroxyvitamin D3 regulation of c-myc during HL-60 cell differentiation and the involvement of HOXB4. J Biol Chem 274: 8437-8444
33. HannSR, EisenmanRN1984Proteinsencodedbythehumanc -myconcogene: differential expression in neoplastic cells. Mol Cell Biol 4:2486-2497
34. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, Clurman BE 2004 The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phos- phorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 101:9085-9090
35. Ikezoe T, Gery S, Yin D, O'Kelly J, Binderup L, Lemp N, Taguchi H, Koeffler HP 2005 CCAAT/enhancer-binding protein A: a molecular target of 1, 25- dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells. Cancer Res 65:4762-4768
36. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D 2005 Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 65:7917-7925
37. Stewart LV, Weigel NL 2005 Role of insulin-like growth factor binding proteins in 1a, 25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate 64:9-19
38. Narayanan R, Edwards DP, Weigel NL 2005 Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol 25:2885-2898
39. Stewart LV, Lyles B, Lin MF, Weigel NL 2005 Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol 97:37-46
40. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Munoz A 2001 Vitamin D(3) promotesthedifferentiationofcoloncarcinomacellsbytheinduction of E-cadherin and the inhibition of /3-catenin signaling. J Cell Biol 154: 369-387
41. Chiariello M, Marinissen MJ, Gutkind JS 2001 Regulation of c-myc expression by PDGF through Rho GTPases. Nat Cell Biol 3:580-586
42. Dominguez-Caceres MA, Garcia-Martinez JM, Calcabrini A, Gonzalez L, Porque PG, Leon J, Martin-Perez J 2004 Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells. Oncogene 23:7378-7390
43. Xie S, Lin H, Sun T, Arlinghaus RB 2002 Jak2 is involvedin c-Mycinduction by Bcr-Abl. Oncogene 21:7137-7146
44. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K, Nakayama KI 2004 Phosphorylation- dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J23:2116-2125
45. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T1998 Geneticalterationsin hormone-refractory recurrent prostate carcinomas. Am J Pathol 153:141-148
46. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J 1998 Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58:2720-2723
47. Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D 2008 Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate 68:935-944
48. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM 2005 Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648
49. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E, Hawksworth DJ, Chen Y, Nau M, Patel V, Vahey M, Gutkind JS, Sreenath T, Petrovics G, Sesterhenn IA, McLeodDG, Srivastava S 2008 TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27:5348 -5353
50. Jensen SS, Madsen MW, Lukas J, Binderup L, BartekJ2001 Inhibitoryeffects of 1aa, 25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 15:1370-1380
51. Feldman D, Zhao XY, Krishnan AV 2000 Vitamin D and prostate cancer. Endocrinology 141:5-9
52. Peehl DM, Krishnan AV, Feldman D 2003 Pathways mediating the growth- inhibitoryactionsofvitaminDinprostatecancer.JNutr133:2461S-2469S
53. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D1994 Antiproliferative effects of 1, 25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54:805-810
54. Blutt SE, Weigel NL 1999 Vitamin D and prostate cancer. Proc Soc Exp Biol Med 221:89-98
55. Peehl DM, Feldman D2003 TheroleofvitaminDandretinoidsincontrolling prostate cancer progression. Endocr Relat Cancer 10:131-140
56. Wiman KG 1993 The retinoblastoma gene: role in cell cycle control and cell differentiation. FASEB J7:841-845
57. Reed SI 1997 Control of the G/S transition. Cancer Surv 29:7-23
58. Zetterberg A, Larsson O, WimanKG 1995 What is the restriction point? Curr Opin Cell Biol 7:835-842
59. Saunders DE, Christensen C, Wappler NL, SchultzJF, LawrenceWD, Malviya VK, Malone JM, Deppe G 1993 Inhibition of c-myc in breast and ovarian carcinoma cells by 1, 25-dihydroxyvitamin D3, retinoic acid and dexametha- sone. Anticancer Drugs 4:201-208
60. Tong WM, Kallay E, Hofer H, Hulla W, ManhardtT, PeterlikM, Cross HS 1998 Growth regulation of human colon cancer cells by epidermal growth factor and 1, 25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression. Eur J Cancer 34:2119 -2125
61. Balaji KC, Koul H, Mitra S, Maramag C, Reddy P, Menon M, Malhotra RK, Laxmanan S 1997 Antiproliferative effects of c-myc antisense oligonucle- otide in prostate cancer cells: a novel therapy in prostate cancer. Urology 50:1007-1015
62. Bartek J, Lukas J2001 PathwaysgoverningG1/S transitionandtheirresponse to DNA damage. FEBS Lett 490:117-122
63. Zhuang SH, Burnstein KL 1998 Antiproliferative effect of 1a, 25-dihydroxyvi- tamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139:1197-1207
64. Leung JY, Ehmann GL, Giangrande PH, Nevins JR 2008 A role for Myc in facilitating transcription activation by E2F1. Oncogene 27:4172-4179
65. Sears R, Ohtani K, Nevins JR 1997 Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol Cell Biol 17:5227-5235
66. Jones TR, Cole MD 1987 Rapid cytoplasmic turnover of c-myc mRNA: requirement of the 3' untranslated sequences. Mol Cell Biol 7:4513-4521
67. Rabbitts PH, Watson JV, Lamond A, Forster A, Stinson MA, Evan G, Fischer W, Atherton E, Sheppard R, Rabbitts TH 1985 Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J 4:2009-2015
68. Vervoorts J, Luscher-Firzlaff J, Luscher B 2006 The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 281:34725-34729
69. Shin S, Bosc DG, Ingle JN, Spelsberg TC, Janknecht R 2008 Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors. J Cell Biochem 105: 866-874
70. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR 2000 Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14:2501-2514
71. Sears RC 2004 The life cycle of C-myc: from synthesis to degradation. Cell Cycle 3:1133-1137
72. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H 1997 Constitutive transcriptional activation by a /3-catenin-Tcf complex in APC-/- colon carcinoma. Science 275:1784-1787
73. Verras M, Sun Z 2006 Roles and regulation of Wnt signaling and /3-catenin in prostate cancer. Cancer Lett 237:22-32
74. Li X, Bijur GN, Jope RS 2002 Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 4:137-144
75. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I 1993 Point mutations in the c-Myc transactivation domain are common in Burkitt's lym- phoma and mouse plasmacytomas. Nat Genet 5:56 -61
76. Smith-Sorensen B, Hijmans EM, Beijersbergen RL, Bernards R 1996 Functional analysis of Burkitt's lymphoma mutant c-Myc proteins. J Biol Chem 271:5513-5518